Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. | Cancers (Basel) | 2020 | 32272636 | PubTator, text mining | PubMed |
| In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG+ve B Cells. | Front Immunol | 2020 | 32265907 | PubTator, text mining | PubMed |
| Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data. | Cancer Manag Res | 2020 | 32256115 | PubTator, text mining | PubMed |
| Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? | Int J Hematol | 2020 | 32253666 | PubTator, text mining | PubMed |
| BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. | Ther Adv Hematol | 2020 | 32231778 | PubTator, text mining | PubMed |
| H and L Chain Affinity Maturation and/or Fab N-Glycosylation Influence Immunoreactivity toward Neutrophil Extracellular Trap Antigens in Rheumatoid Arthritis Synovial B Cell Clones. | J Immunol | 2020 | 32221039 | PubTator, text mining | PubMed |
| Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. | J Immunother Cancer | 2020 | 32217767 | PubTator, text mining | PubMed |
| Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients. | J Blood Med | 2020 | 32210655 | PubTator, text mining | PubMed |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. | Blood | 2020 | 32206772 | PubTator, text mining | PubMed |
| Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. | Clin Cancer Res | 2020 | 32198151 | PubTator, text mining | PubMed |
| Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. | Clin Lymphoma Myeloma Leuk | 2020 | 32197990 | PubTator, text mining | PubMed |
| Drug Resistance in Non-Hodgkin Lymphomas. | Int J Mol Sci | 2020 | 32197371 | PubTator, text mining | PubMed |
| Correction to: IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications. | Virchows Arch | 2020 | 32189121 | PubTator, text mining | PubMed |
| Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. | Genome Med | 2020 | 32188505 | PubTator, text mining | PubMed |
| The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. | Cancer Med | 2020 | 32187452 | PubTator, text mining | PubMed |
| Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. | J Hematol Oncol | 2020 | 32183871 | PubTator, text mining | PubMed |
| Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies. | Cells | 2020 | 32183335 | PubTator, text mining | PubMed |
| NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. | Noncoding RNA | 2020 | 32182990 | PubTator, text mining | PubMed |
| Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets. | Cancers (Basel) | 2020 | 32182763 | PubTator, text mining | PubMed |
| Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. | Curr Oncol Rep | 2020 | 32172299 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=60